Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of varying degrees of hepatic impairment on the single dose safety and pharmacokinetic profile of lurasidone: an open-label phase I single dose non-randomised oral administration study.

Next Previous
Trial Profile

The effect of varying degrees of hepatic impairment on the single dose safety and pharmacokinetic profile of lurasidone: an open-label phase I single dose non-randomised oral administration study.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Bipolar disorders; Major depressive disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Dainippon Sumitomo Pharma

Most Recent Events

  • 16 Jan 2012 Additional locations identified as reported by ISRCTN: Current Controlled Trials.
  • 27 Apr 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top